Crinetics Pharmaceuticals (CRNX) Shares Outstanding (Diluted Average) (2020 - 2026)
Crinetics Pharmaceuticals (CRNX) recorded quarterly Shares Outstanding (Diluted Average) of $104.1 million in Q1 2026, up 10.68% quarter-over-quarter from $94.1 million in Q4 2025, and up 11.81% on a YoY basis from $93.1 million in Q1 2025.
Crinetics Pharmaceuticals (CRNX) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' Shares Outstanding (Diluted Average) history runs 7 years deep, the most recent figure standing at $104.1 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 11.81% year-over-year to $104.1 million; the TTM figure through Mar 2026 stood at $104.1 million (up 11.81% YoY), while the FY2025 annual figure was $94.1 million, up 16.43% from the prior year.
- Shares Outstanding (Diluted Average) was $104.1 million for Q1 2026 at Crinetics Pharmaceuticals, up from $94.1 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $104.1 million in Q1 2026 to a low of $47.7 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $71.3 million across 5 years, with a median of $72.3 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Diluted Average) jumped 49.86% in 2022, then grew 2.3% in 2023.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $52.0 million in 2022, then increased by 11.71% to $58.1 million in 2023, then jumped by 39.11% to $80.8 million in 2024, then advanced by 16.43% to $94.1 million in 2025, then climbed by 10.68% to $104.1 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $104.1 million (Q1 2026), $94.1 million (Q4 2025), and $94.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Crinetics Pharmaceuticals | 3.75 Bn | 3.75 Bn | 10.53 Mn | 104.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 104.10 Mn |
| Dec 31, 2025 | 94.06 Mn |
| Sep 30, 2025 | 94.22 Mn |
| Jun 30, 2025 | 93.45 Mn |
| Mar 31, 2025 | 93.10 Mn |
| Dec 31, 2024 | 80.78 Mn |
| Sep 30, 2024 | 77.17 Mn |
| Jun 30, 2024 | 75.69 Mn |
| Mar 31, 2024 | 72.29 Mn |
| Dec 31, 2023 | 58.07 Mn |
| Sep 30, 2023 | 55.00 Mn |
| Jun 30, 2023 | 54.09 Mn |
| Mar 31, 2023 | 53.91 Mn |
| Dec 31, 2022 | 51.98 Mn |
| Sep 30, 2022 | 53.77 Mn |
| Jun 30, 2022 | 52.52 Mn |
| Mar 31, 2022 | 47.71 Mn |
| Dec 31, 2021 | 38.44 Mn |
| Sep 30, 2021 | 38.31 Mn |
| Jun 30, 2021 | 35.05 Mn |